Joseph Pham, MD
Ophthalmology · Tacoma, WANPI 1891727814
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,785 of the $9,785 with a category attached, or 89.8%. 23 manufacturers reported payments, led by AbbVie at 35.7% of the total. Among ophthalmology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 245 payments — averaging $39.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Glaukos Corporation$3K
- Johnson & Johnson Surgical Vision, Inc.$707
- Alcon$435
- Rxsight Inc$211
- Sun Pharmaceutical Industries Inc.$201
- plus $1K from 17 others
What the payments were for
- Consulting fees$1,00010%
- Food & beverage$8,78590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 98 | $3,497 |
| Glaukos Corporation | 52 | $3,428 |
| Johnson & Johnson Surgical Vision, Inc. | 18 | $707 |
| Alcon | 16 | $435 |
| Rxsight Inc | 9 | $211 |
| Sun Pharmaceutical Industries Inc. | 9 | $201 |
| Astellas Pharma US Inc | 2 | $157 |
| Rayner Intraocular Lenses Limited | 2 | $151 |
| NEW World Medical,inc. | 2 | $134 |
| Genentech USA, Inc. | 1 | $110 |
| Aerie Pharmaceuticals, Inc. | 5 | $104 |
| Thea Pharma Inc. | 5 | $104 |
| Biotissue Holdings Inc. | 5 | $98 |
| Oyster Point Pharma, Inc. | 3 | $78 |
| Dompe US, Inc. | 2 | $65 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $59 |
| Bausch & Lomb Americas Inc. | 3 | $56 |
| Kala Pharmaceuticals, Inc. | 3 | $51 |
| Tarsus Pharmaceuticals, Inc. | 2 | $47 |
| Novartis | 2 | $37 |
| Sight Sciences, Inc. | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Iridex Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iStent inject W$681
- XEN$560
- iAccess Precision Blade$323
- iStent$299
- Tecnis IOL$239
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$183
- iStent infinite Trabecular Micro-Bypass System Model iS3$183
- iDose$174
- KXL System$161
- iStent Trabecular Micro-Bypass Stent System$140
- Izervay$137
- IACCESS$135
- RAYNER CATARACT SET 1$132
- RayOne EMV$132
- RayOne Spheric$132
- RayOne Aspheric$132
- CATALYS SYSTEM$125
- iDoseTR$124
- iStent Infinite$124
- XEN GLAUCOMA TREATMENT SYSTEM$123
How this compares
$9,785 in reported general payments places this provider in the 90th percentile of 428 ophthalmology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 625 | $293,444 |
| LumiganBimatoprost | 373 | $179,518 |
| RestasisCyclosporine | 151 | $153,502 |
| RhopressaNetarsudil Mesylate | 178 | $94,196 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 209 | $61,778 |
| VyzultaLatanoprostene Bunod | 88 | $47,953 |
| CombiganBrimonidine Tartrate/Timolol | 106 | $43,333 |
| Alphagan PBrimonidine Tartrate | 80 | $38,081 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 185 | $35,626 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 193 | $32,952 |
| Prednisolone Acetate | 682 | $31,100 |
| Latanoprost | 2,416 | $27,308 |
| Travoprost | 212 | $24,732 |
| Brimonidine Tartrate | 834 | $24,345 |
| Brinzolamide | 112 | $20,746 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $3,497 | $414,433710 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $104 | $387,640803 claims |
| AlconSimbrinza, Azopt | $435 | $70,567222 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Zirgan | $56 | $55,715105 claims |
| NovartisTravatan Z | $37 | $16,79723 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $59 | $9,99560 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 428 ophthalmology providers in Washington.
Other ophthalmology in Tacoma
- Andrew KopsteinTacoma$57K
- Clifton PerryTacoma$50K
- Niraj PatelTacoma$13K
- Victor ChiuTacoma$10K
- Jacob LightTacoma$10K
- Mark NelsonTacoma$7K
- Francis GeisslerTacoma$6K
- Laura PerimanSeattle$1.7M
- Sheldon CowenSeattle$560K
- Todd SchneidermanSilverdale$200K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.